mdv 3100

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist (IC50=36 nM in LNCaP) that activates autophagy, exhibits antitumor activity, and is commonly used in treating desmoplasia-resistant prostate cancer.

N-desmethyl Enzalutamide (N-desmethyl MDV 3100) is the active Enzalutamide metabolite.It is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide.

Enzalutamide-d3 (Deutenzalutamide-d3) is a deuterium-labeled form of the androgen receptor antagonist enzalutamide, retaining potent anti-androgen and antineoplastic activity with an IC50 of 36 nM in LNCaP prostate cancer cells, and is primarily used in pharmacokinetic, metabolic tracing, and drug interaction studies.

Enzalutamide carboxylic acid is an antagonist of androgen receptor (AR) .

N-desmethyl Enzalutamide D6 is a deuterium labeled N-desmethyl Enzalutamide.